In:
Cancer, Wiley, Vol. 121, No. 16 ( 2015-08-15), p. 2749-2756
Abstract:
This phase 2 study demonstrates that lenvatinib produces encouraging objective response and progression‐free survival rates in patients with radioiodine‐refractory, differentiated thyroid cancer and also has a well defined safety profile. Lenvatinib also exhibits activity in patients who previously received vascular endothelial growth factor/vascular endothelial growth factor receptor‐targeted therapies.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v121.16
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1